Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the Rel proteins in the nuclear factor-κB family

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4589-4597

  Fan, Gaofeng ^a,b   Fan, Yongjun ^a,e   Gupta, Nupur ^a,b,f   Matsuura, Isao ^a,g   Liu, Fang ^a,b   Xiao, Zhen Zhou ^d   Kun, Ping Lu ^d   Gélinas, Céline ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f Jain Foundation Inc   (United States)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JUGLONE; PEPTIDYLPROLYL ISOMERASE PIN1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR REL;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CHICKEN; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOCYTE TRANSFORMATION; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; ANIMALS; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CHICKENS; HUMANS; LYMPHOMA; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; NAPHTHOQUINONES; NF-KAPPA B; ONCOGENE PROTEINS V-REL; PEPTIDYLPROLYL ISOMERASE; PROTEIN BINDING; PROTEIN TRANSPORT; SEQUENCE HOMOLOGY, AMINO ACID; UP-REGULATION;

EID: 66349093637     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4117     Document Type: Article

References (50)

1. Bonizzi G, Karin M. The two N F-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288 (Pubitemid 38610351)
2. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-κB. Mol Cell 2004;13:853-865
3. Gupta N, Delrow J, Drawid A, Sengupta AM, Fan G, Gelinas C. Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins. Cancer Res 2008;68:808-814
4. Majid SM, Liss AS, You M, Bose HR. The suppression of SH3BGRL is important for v-Rel-mediated transformation. Oncogene 2006;25:756-768 (Pubitemid 43214702)
5. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-κB. Oncogene 2006;25:6800-6816 (Pubitemid 44657853)
6. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down-regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol Cell Biol 2003;23:4713-4727 (Pubitemid 36740458)
7. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005;115:2625-2632 (Pubitemid 41434385)
8. Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996;380:544-547 (Pubitemid 26111332)
9. Ranganathan R, Lu KP, Hunter T, Noel JP. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 1997;89:875-886 (Pubitemid 27513514)
10. Yaffe MB, Schutkowski M, Shen M, et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997;278:1957-1960 (Pubitemid 28013239)
11. Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 2007;8:904-916 (Pubitemid 47622559)
12. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003;12:1413-1426 (Pubitemid 38037011)
13. Wulf GM, Ryo A, Wulf GG, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001;20:3459-3472 (Pubitemid 32634353)
14. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-2960 (Pubitemid 28022831)
15. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin, Jr. AS. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 2000;19:1123-1131 (Pubitemid 30157541)
16. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874 (Pubitemid 34028664)
17. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005;37:382-390 (Pubitemid 40490488)
18. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-132 (Pubitemid 43202662)
19. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-563 (Pubitemid 47525152)
20. Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004;22:3937-3949 (Pubitemid 41079876)
21. Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007;109:1692-1700 (Pubitemid 46239604)
22. Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-688 (Pubitemid 38145555)
23. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88-95. (Pubitemid 36745276)
24. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-16647 (Pubitemid 34967682)
25. Yeh ES, Means AR. PIN1, the cell cycle and cancer. Nat Rev Cancer 2007;7:381-388 (Pubitemid 46652482)
26. Fan Y, Rayet B, Gélinas C. Divergent C-terminal transactivation domains of Rel/NF-κB proteins are critical determinants of their oncogenic potential in lymphocytes. Oncogene 2004;23:1030-1042 (Pubitemid 38269957)
27. Nacheva E, Dyer MJ, Metivier C, et al. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood 1994;84:3422-3428 (Pubitemid 24352905)
28. Zhang JY, Olson W, Ewert D, Bargmann W, Bose HR, Jr. The v-rel oncogene of avian reticuloendotheliosis virus transforms immature and mature lymphoid cells of the B cell lineage in vitro. Virology 1991;183:457-466
29. Gilmore TD, Cormier C, Jean-Jacques J, Gapuzan ME. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene 2001;20:7098-7103 (Pubitemid 33052202)
30. Romieu-Mourez R, Kim DW, Shin SM, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003;23:5738-5754 (Pubitemid 36951337)
31. Starczynowski DT, Reynolds JG, Gilmore TD. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene 2003;22:6928-6936 (Pubitemid 37386693)
32. Feuerhake F, Kutok JL, Monti S, et al. NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392-1399 (Pubitemid 41129606)
33. Lu PJ, Zhou XZ, Liou YC, Noel JP, Lu KP. Critical role of WW domain phosphorylation in regulating phosphoserine binding activity and Pin1 function. J Biol Chem 2002;277:2381-2384 (Pubitemid 34953258)
34. Hennig L, Christner C, Kipping M, et al. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. Biochemistry 1998;37:5953-5960 (Pubitemid 28196748)
35. Galas MC, Dourlen P, Begard S, et al. The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J Biol Chem 2006;281:19296-19304 (Pubitemid 44035434)
36. Esnault S, Braun RK, Shen ZJ, et al. Pin1 modulates the type 1 immune response. PLoS ONE 2007;2:e226.
37. Kesavapany S, Patel V, Zheng YL, et al. Inhibition of Pin1 reduces glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in neurons. Mol Biol Cell 2007;18:3645-3655 (Pubitemid 47378701)
38. Weniger MA, Gesk S, Ehrlich S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 2007;46:406-415 (Pubitemid 46411331)
39. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001;97:2798-2807
40. Pang RW, Lee TK, Man K, et al. PIN1 expression contributes to hepatic carcinogenesis. J Pathol 2006;210:19-25. (Pubitemid 44288176)
41. Pang R, Yuen J, Yuen MF, et al. PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004;23:4182-4186 (Pubitemid 38747951)
42. Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003;63:6244-6251 (Pubitemid 37255170)
43. Wulf G, Garg P, Liou YC, Iglehart D, Lu KP. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J 2004;23:3397-3407 (Pubitemid 39209163)
44. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-318 (Pubitemid 38584820)
45. Yeh ES, Lew BO, Means AR. The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability. J Biol Chem 2006;281:241-251 (Pubitemid 43671183)
46. Finn G, Lu KP. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets 2008;8:223-229
47. Sachdev S, Hannink M. Loss of IκBα-mediated control over nuclear import and DNA binding enables oncogenic activation of c-Rel. Mol Cell Biol 1998;18:5445-5456 (Pubitemid 28388127)
48. Aguilera C, Fernandez-Majada V, Ingles-Esteve J, Rodilla V, Bigas A, Espinosa L. Efficient nuclear export of p65-IκBα complexes requires 14-3-3 proteins. J Cell Sci 2006;119:3695-3704 (Pubitemid 44501873)
49. Xu YX, Hirose Y, Zhou XZ, Lu KP, Manley JL. Pin1 modulates the structure and function of human RNA polymerase II. Genes Dev 2003;17:2765-2776 (Pubitemid 37463286)
50. Fila C, Metz C, van der Sluijs P. Juglone inactivates cysteine-rich proteins required for progression through mitosis. J Biol Chem 2008;283:21714-21724